新型重组血管内皮抑制素联合顺铂治疗癌性胸水疗效研究

[目的]探讨新型重组血管内皮抑制素(恩度)联合顺铂(DDP)腔内注射治疗癌性胸水的临床疗效和不良反应。[方法]随机对照观察46例恶性肿瘤并发胸水患者治疗情况,其中采用新型重组血管内皮抑制素(恩度)联合顺铂(DDP)腔内注射治疗21例为治疗组,单纯DDP治疗25例为对照组。[结果]治疗组和对照组总有效率(CR+PR)分别为61.90%、40%(u=3.48,P﹤0.05),差异有统计学意义。治疗组和对照组总的不良反应率分别为33.33%,28%;差异无统计学意义(χ2=0.83,P﹥0.05)。[结论新型重组血管内皮抑制素(恩度)联合顺铂(DDP)腔内注射治疗癌性胸水安全有效,可以作为临床上治疗癌性胸水选择方法之一。

STUDY OF NEW RECOMBINANT ENDOSTATIN COMBINED WITH CISPLATIN INJECTION FOR TREATMENT OF MALIGNANT PLEURAL EFFUSION

[Objective]To explore the new recombinant endostatin combined with cisplatin(DDP)injection for treatment of malignant pleural effusion.[Methods]Randomized controlled 46 cases complicated with malignant pleural effusion patients,of which using new recombinant endostatin combined with cisplatin(DDP)injection for the treatment of 21 patients,25 patients DDP alone as control group.[Results]The total effective rates(CR + PR)in treatment group and control group were respectively 61.90%,40%(u = 3.48,P﹤0.05);the difference was statistically significant.The rates of adverse reactions in treatment group and control group were respectively 33.33%,28%;the difference was not statistically significant(χ2 = 0.83,P﹥ 0.05).[Conclusion]The novel recombinant endostatin combined with cisplatin(DDP)injection for treatment of malignant pleural effusion is safe and effective,can be used as one of clinical treatment methods of malignant pleural effusion.